ImClone Systems Incorporated was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology.[1] It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City.[1] On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.[2]
^ ab"ImClone Systems Corporation". Company Insight Center. Bloomberg Businessweek. Snapshot. Archived from the original on 2009-05-18. Retrieved 2013-12-25.
^"Eli Lilly US Locations". R&D Locations. Eli Lilly and Company. Archived from the original on 20 October 2018. Retrieved 19 October 2018.
Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company. ImClone's stock...
Exchange Commission and U.S. Attorney probe into trading in the shares of ImCloneSystems resulted in a widely publicized criminal case, which resulted in prison...
2012. In 2004, Stewart was convicted of felony charges related to the ImClone stock trading case; she served five months in federal prison for fraud...
such as those affecting Enron, Tyco International, Adelphia, Peregrine Systems and WorldCom, when the concept was strongly emphasized in the Sarbanes–Oxley...
drug by the pharmaceutical company ImCloneSystems, Inc. Paul Goldberg documented the missteps in FDA filings by ImClone that led to the failure to secure...
was founded in 2009 by Samuel D. Waksal, founder and former CEO of ImCloneSystems, now fully merged into Eli Lilly and Company. Waksal had served a federal...
Yeda vs Aventis/Imclone case" (PDF). Archived from the original (PDF) on 2011-09-27. Retrieved 2012-05-25. "Yeda Research v. ImcloneSystems, et al". Archived...
Internet Icahn Enterprises conglomerates Iconix Brand Group fashion ImCloneSystems pharmaceuticals ImpreMedia media Infor software Inner City Broadcasting...
designed for the treatment of solid tumors. Icrucumab was developed by ImCloneSystems Inc. It is undergoing Phase I trials. "Statement On A Nonproprietary...
developed for the treatment of solid tumors. This drug was developed by ImCloneSystems Inc. It was isolated from a native phage display library from Dyax...
Waksal is the founder and former CEO of the biopharmaceutical company ImCloneSystems. In October 2002, he pleaded guilty to charges of securities fraud...
IMCL may refer to: Indian Made Country Liquor or Desi daru ImCloneSystems This disambiguation page lists articles associated with the title IMCL. If...
2006, he was the senior vice president, general counsel and CCO of ImCloneSystems, which was later acquired by Eli Lilly and Company. From 2001 to 2010...
obstruction of justice, and lying to an FBI agent. She sold 3,928 shares of ImCloneSystems, thereby avoiding a loss of $45,673. The next day, the Food and Drug...
Memphis Grizzlies Samuel D. Waksal (1947–), French-born founder of ImCloneSystems, Kadmon Corporation Herbert Wertheim (1939–), founder of eye care products...
Archived from the original on April 6, 2012. Retrieved November 1, 2011. "Ex-ImClone boss admits fraud". BBC News. October 15, 2002. Archived from the original...
treatment of melanoma. It targets TYRP1. Flanvotumab was developed by ImCloneSystems, now owned by Eli Lilly. "Statement On A Nonproprietary Name Adopted...
development was abandoned after phase I trials. Narnatumab was developed by ImCloneSystems. "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab"...
Nobel prize. However the dissimilarity between murine and human immune systems led to the clinical failure of these antibodies, except in some specific...
biological half-life of 11 days. Olaratumab was originally developed by ImCloneSystems, which was acquired by Eli Lilly in 2008. A Phase I clinical trial...
antibody for the treatment of solid tumors. This drug was developed by ImCloneSystems, since acquired by Eli Lilly, using phage display technology from Dyax...
included WorldCom Inc., Tyco International Ltd., Vivendi Universal SA and ImCloneSystems Inc. In 2018, she won the Lifetime Achievement Award from the Gerald...
was CEO from February 2011 until February 2012, formerly employed by ImcloneSystems. Savient declared bankruptcy in 2013. The drug was selling at $5,390...
Molecular cloning is a set of experimental methods in molecular biology that are used to assemble recombinant DNA molecules and to direct their replication...
worldwide, apart from North America. (Cetuximab was discovered by ImcloneSystems, and is marketed in North America by Bristol-Myers Squibb.) Other areas...
Global Information